Journal
CANCER BIOLOGY & THERAPY
Volume 19, Issue 5, Pages 347-348Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2018.1423926
Keywords
androgen; Cancer Biology; castration; independent; medicine; personalized; receptor; resistance
Categories
Ask authors/readers for more resources
Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and their impact in the future management of castration-resistant prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available